About this trial
The current prospective observational pilot study aims to evaluate the endocrine profile of a single-injection protocol (single CFA + daily oral administration of CC).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Single group
Treatments tested in this trial
Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1
DrugOn day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.
Clomiphene Citrate (CC) 100 mg/day from D1
DrugOn day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
Monitoring cycle
Diagnostic testScan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.
Treatment groups
Trial outcomes
Primary outcomes
Estradiol
Estradiol levels
Progesterone
Progesterone levels
Follicle stimulating hormone (FSH)
FSH levels
Luteinizing hormone (LH)
LH levels
Secondary outcomes
Days of stimulation
Number of oocytes retrieved (COCs)
Number of MII oocytes
Follicular Output Rate (FORT)
expressed as the ratio between the total number of oocytes retrieved at oocyte pick-up and the number of antral follicles available at the start of stimulation
Sponsors and contacts
Click on the lead sponsor to view all of their trials.